VTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc. is a late-stage biopharmaceutical company listed on Nasdaq under the ticker VTVT. The company is focused on developing oral small-molecule drug candidates for diabetes and other chronic diseases. Its lead program is cadisegliatin (TTP399), an orally administered, liver-selective glucokinase activator being evaluated in a Phase III clinical trial for type 1 diabetes. In addition to this program, vTv Therapeutics is advancing a range of molecules across multiple chronic-disease indications. The company also has a license agreement with Newsoara Biopharma Co., Ltd. covering the development and commercialization of a phosphodiesterase type 4 inhibitor program. vTv Therapeutics was incorporated in 2015 and is headquartered in High Point, North Carolina.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VTVT
|
$32.92
|
-0.5% Downside
|
Fair
|
$54.33
|
64.3% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
182.3x
|
4.6x
|
11.1x
|
401.8 M
|
312.4 M
|
0.0%
|
17.3%
|
24.3
|
—
|
-462.4%
|
